GSK PLC (LSE:GSK)
£ 13.97 0.16 (1.16%) Market Cap: 57.00 Bil Enterprise Value: 69.85 Bil PE Ratio: 22.90 PB Ratio: 4.07 GF Score: 69/100

GlaxoSmithKline PLC to Discuss Pivotal DREAMM-2 Data on Belantamab Mafodotin (GSK'916) Call Transcript

Dec 17, 2019 / 05:00PM GMT
Release Date Price: £17.91 (+0.79%)
Operator

Good day, everyone, and welcome to the DREAMM-2 call hosted by Sarah Elton-Farr. My name is Steve and I'm your event manager. (Operator Instructions). I'd like to advise all parties this conference is being recorded for replay purposes.

And now I'd like to hand over to Sarah.

Sarah Elton;Farr
GlaxoSmithKline plc - Head of IR

Thank you. Good afternoon. Thank you for joining us here today on our call to discuss the data from the DREAMM-2 study, which was published yesterday in the Lancet Oncology. Our speakers today are Dr. Hal Barron, Chief Scientific Officer and President of R&D; Dr. Peter Voorhees, member of the Plasma Cell Disorders division from the Levine Cancer Institute; Dr. Axel Hoos, Head of Oncology R&D; and Luke Miels, President of Global Pharmaceuticals. We also have Christine Roth, Global Oncology Therapy Area Head; and Ira Gupta, Medicine Development Lead for belantamab, on the line for Q&A.

Before we begin, I'll need to refer you to our cautionary statements on slide 2.

And with that, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot